Few adverse effects were reported for the orally administered drug CNV2197944 in both young and elderly patients, indicating that the drug has an “optimal profile for a chronic pain medication,” the company said.
Convergence is currently developing a Phase II trial for the drug.
Related Articles on Pain Management:
RS Medical to Launch Nimbus Radiofrequency Ablation Device
University of New England Researcher Receives $140K Grant to Study Cancer Pain
Memorial Hospital of Union County, Pain Management Group Open Pain Center
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
